Myriad Genetics Inc Stock Prediction
AI-powered sentiment analysis and prediction trends for MYGN, updated each market day.
MYGN AI Sentiment
AI sees no strong directional signal for Myriad Genetics Inc stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Myriad Genetics Inc
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Sector
Exchange
Market Cap
$415,176,252
Cap Tier
Employees
2,700
Headquarters
SALT LAKE CITY, UT
Listed Since
Oct. 6, 1995
Website
MYGN Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MYGN Volatility
Myriad Genetics Inc has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
